Idroxioleic Acid: First-in-Class Sphingolipid Regulator and Glioma Cell Autophagy Inducer With Antitumor Activity in Patients With Refractory Glioma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma
Br. J. Cancer 2023 Jul 24;[EPub Ahead of Print], J Lopez, J Lai-Kwon, R Molife, L Welsh, N Tunariu, D Roda, P Fernández-García, V Lladó, AG McNicholl, CA Rosselló, RJ Taylor, A Azaro, J Rodón, J Sludden, GJ Veal, R Plummer, A Urruticoechea, A Lahuerta, K Mujika, PV EscribáFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.